Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2557-2564

  Xu, Chun Fang ^a,b,c,d,e   Bing, Nan X ^a,b,c,d,e   Ball, Howard A ^a,b,c,d,e   Rajagopalan, Dilip ^a,b,c,d,e   Sternberg, Cora N ^a,b,c,d,e   Hutson, Thomas E ^a,b,c,d,e   De Souza, Paul ^a,b,c,d,e   Xue, Zhengyu G ^a,b,c,d,e   McCann, Lauren ^a,b,c,d,e   King, Karen S ^a,b,c,d,e   Ragone, Leigh J ^a,b,c,d,e   Whittaker, John C ^a,b,c,d,e   Spraggs, Colin F ^a,b,c,d,e   Cardon, Lon R ^a,b,c,d,e   Mooser, Vincent E ^a,b,c,d,e   Pandite, Lini N ^a,b,c,d,e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d TEXAS ONCOLOGY   (United States)

^e ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; INTERLEUKIN 8; PAZOPANIB; PREGNANE X RECEPTOR; PREGNANE X RECEPTOR NR1I2; THREONINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HIF1A; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERMLINE MICRONUCLEUS; HUMAN; HYPOTHESIS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; WILD TYPE;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CROSS-OVER STUDIES; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENOTYPE; GERM-LINE MUTATION; HUMANS; KIDNEY NEOPLASMS; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONAMIDES;

EID: 79959316184     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.9110     Document Type: Article

References (43)

1. Sonpavde G, Hutson TE: Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9:115-119, 2007 (Pubitemid 46332383)
2. U.S. Department of Health and Human Services Food & Drug Administration: Pazopanib. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ ucm187509.htm
3. Kidney Cancer Canada: Votrient (pazopanib) Approved by Health Canada for the Treatment of Renal Cell Carcinoma. http://www.kidneycancercanada.org/main. php?p=600&lan=1. 2010
4. Davis J: Pazopanib wins conditional EU approval for renal cell carcinoma. http://www.medconnect.com.au/tabid/84/s2/Endocrinology/ct1/c337246/Pazopanib- Wins-Conditional-EU-Approval-for-Renal-Cell-Carcinoma/Default.aspx
5. Australian Government Department of Health and Ageing: Drugs designated as orphan drugs: Pazopanib (PATORMA). http://www.tga.gov.au/docs/html/orphand2. htm#p
6. Instituto de Salud Publica de Chile: Votrient coated tablets. http://200.68.11.21/RegistrosISP/fiFichaProducto.asp?RegistroISP=F-18018/10
7. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
8. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999 (Pubitemid 29368255)
9. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26: 4672-4678, 2008
10. Schultheis AM, Lurje G, Rhodes KE, et al: Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14:7554-7563, 2008
11. Xu CF, Reck BH, Xue Z, et al: Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 102: 1371-1377, 2010
12. Xu CF, Reck BH, Goodman VL, et al: Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol [Epub ahead of print on February 12, 2011]
13. Hutson TE, Davis ID, Machiels JP, et al: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28:475-480, 2010
14. Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al: Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 338:299-305, 2005 (Pubitemid 41540570)
15. Wong M, Balleine RL, Collins M, et al: CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75:529-538, 2004 (Pubitemid 38746603)
16. van Erp NP, Eechoute K, van der Veldt AA, et al: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406-4412, 2009
17. Lamba J, Lamba V, Strom S, et al: Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36:169-181, 2008
18. Andrews E, Armstrong M, Tugwood J, et al: A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 51:1656-1664, 2010
19. Kerb R: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234:4-33, 2006
20. Mizuarai S, Aozasa N, Kotani H: Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246, 2004 (Pubitemid 38240926)
21. Kim HS, Sunwoo YE, Ryu JY, et al: The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 64:645-654, 2007 (Pubitemid 47568815)
22. Wang Y, Zheng Y, Zhang W, et al: Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50:760-767, 2007 (Pubitemid 47243798)
23. Steeghs N, Gelderblom H, Wessels J, et al: Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors. Invest New Drugs 29:137-143, 2011
24. Kawahara C, Forster T, Chapman K, et al: Genetic association analysis of the IGFBP7, ADAMTS3, and IL8 genes as the potential osteoarthritis susceptibility that maps to chromosome 4q. Ann Rheum Dis 64:474-476, 2005
25. Hull J, Thomson A, Kwiatkowski D: Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 55:1023-1027, 2000
26. Kato M, Okugawa G, Wakeno M, et al: Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol 19:718-725, 2009
27. Boyarskikh UA, Zarubina NA, Biltueva JA, et al: Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia. Eur J Hum Genet 17:1688-1691, 2009
28. Tanimoto K, Yoshiga K, Eguchi H, et al: Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24: 1779-1783, 2003 (Pubitemid 37408141)
29. Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11:992-997, 2005 (Pubitemid 41294446)
30. Huang D, Ding Y, Zhou M, et al: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071, 2010
31. Rini BI, Zhou M, Aydin H, et al: Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). J Clin Oncol 28:342s, 2010 (suppl; abstr 4501)
32. Hacking D, Knight JC, Rockett K, et al: Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun 5:274-282, 2004 (Pubitemid 38961160)
33. Taguchi A, Ohmiya N, Shirai K, et al: Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 14:2487-2493, 2005 (Pubitemid 41752706)
34. Chen MH, Tzeng CH, Chen PM, et al: VEGF -460T -> C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J [Epub ahead of print on June 8, 2010]
35. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46: 293-298, 2004 (Pubitemid 39487303)
36. Stevens A, Soden J, Brenchley PE, et al: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812-816, 2003 (Pubitemid 36231981)
37. Kliewer SA, Goodwin B, Willson TM: The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev 23:687-702, 2002 (Pubitemid 35191629)
38. Zhang J, Kuehl P, Green ED, et al: The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572, 2001 (Pubitemid 32953582)
39. GlaxoSmithKline: Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ). http:// clinicaltrials.gov/ct2/show/NCT00720941
40. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 57:289-300, 1995
41. Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27: 5794-5799, 2009
42. Buyse M, Sargent DJ, Grothey A, et al: Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7:309-317, 2010
43. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health: International HapMap Project. htt://hapmap.ncbi.nlm.nih.gov